A fraction of recurrent IDH-mutant gliomas develops resistance against TMZ by acquiring mutations in MMR genes, leading secondarily to a hypermutated genotype [10, 13, 36, 44, 47]. The gene discussed is IDH2; the disease is central nervous system cancer.